PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its ...
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be ...
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $32 and keeps a Sell rating on the shares. The firm updated the ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...
The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
3d
Irish Examiner on MSNNew investments show Ireland still first port of call for US firmsBusiness Editor Alan Healy reports on Ireland's enduring appeal as a location for US firms to set up shop — despite a ...
Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...
In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results